1,077 results

#172922-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSynapsin1-axon-jGCaMP8m-P2A-mRuby3 (#172922). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-jGCaMP8m-P2A-mRuby3 plasmid DNA. Syn-driven expression of calcium sensor jGCaMP8m in axons with cytosolic expression of mRuby3. These AAV preparations are suitable purity for injection into animals.

GENIE Project

July 12, 2023

Academic Institutions and Nonprofits only

#20071-AAV1

Ready-to-use AAV1 particles produced from pACAGW-ChR2-Venus-AAV (#20071). In addition to the viral particles, you will also receive purified pACAGW-ChR2-Venus-AAV plasmid DNA. CAG-driven, channelrhodopsin fused to Venus for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karel Svoboda

Leopoldo et al Nature. 2009 Jan 18.

Feb. 21, 2018

Academic Institutions and Nonprofits only

#99039-AAV1

Ready-to-use AAV1 particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

Feb. 7, 2018

Academic Institutions and Nonprofits only

#137155-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon-iC++-EYFP (#137155). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon-iC++-EYFP plasmid DNA. nEF-driven, Cre and Flp-dependent expression of chloride-conducting channelrhodopsin iC++-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Dec. 1, 2020

Academic Institutions and Nonprofits only

#55641-AAV2

Ready-to-use AAV2 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Sept. 27, 2023

Academic Institutions and Nonprofits only

#125560-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-dLight1.3b (#125560). In addition to the viral particles, you will also receive purified pAAV-CAG-dLight1.3b plasmid DNA. CAG-driven expression of dLight1.3b dopamine sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

May 6, 2021

Academic Institutions and Nonprofits only

#99133-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-fDIO-mNeonGreen (#99133). In addition to the viral particles, you will also receive purified pAAV-CAG-fDIO-mNeonGreen plasmid DNA. CAG-driven, Flp-dependent mNeonGreen expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

Jan. 6, 2022

Academic Institutions and Nonprofits only

#50465-AAV1.T

Ready-to-use AAV1 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

July 12, 2019

Academic Institutions and Nonprofits only

#112677-AAV5

Ready-to-use AAV5 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Aug. 26, 2019

Academic Institutions and Nonprofits only

#123309-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-GRAB_NE1h (#123309). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_NE1h plasmid DNA. hSyn-driven expression of GRAB-NE1h norepinephrine sensor in neurons. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Feng et al Neuron. 2019 May 22;102(4):745-761.e8. d

June 22, 2020

Academic Institutions and Nonprofits only

#137130-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-BFP (#137130). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-BFP plasmid DNA. EF1a-driven, Cre-dependent expression of BFP (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

March 19, 2021

Academic Institutions and Nonprofits only

#105551-AAVrg

Ready-to-use AAV Retrograde particles produced from pENN.AAV.CamKII.HI.GFP-Cre.WPRE.SV40 (#105551). In addition to the viral particles, you will also receive purified pENN.AAV.CamKII.HI.GFP-Cre.WPRE.SV40 plasmid DNA. Expression of GFP-Cre from CamKII promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Oct. 21, 2024

Academic Institutions and Nonprofits only

#50942-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn1-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA (#50942). In addition to the viral particles, you will also receive purified pAAV-hSyn1-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA plasmid DNA. GCaMP6s calcium sensor and bicistronic, physically separate mRuby2 expression under a human synapsin1 promoter. These AAV preparations are suitable purity for injection into animals.

Tobias Bonhoeffer, Mark Huebener, Tobias Rose

Rose et al Science. 2016 Jun 10;352(6291):1319-22.

March 7, 2018

Academic Institutions and Nonprofits only

#178329-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn.iGluSnFR3.v857.PDGFR (#178329). In addition to the viral particles, you will also receive purified pAAV.hSyn.iGluSnFR3.v857.PDGFR plasmid DNA. Synapsin-driven, third generation glutamate sensor iGluSnFR3, variant 857. These AAV preparations are suitable purity for injection into animals.

Kaspar Podgorski

Aggarwal et al Nat Methods. 2023 May 4. doi: 10.1038/s4

May 16, 2023

Academic Institutions and Nonprofits only

#84446-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (#84446). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] plasmid DNA. CAG-driven, Cre-dependent expression of Jaws-KGC-tdTomato-ER2 for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

March 18, 2024

Academic Institutions and Nonprofits only

#100835-AAV2

Ready-to-use AAV2 particles produced from pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 (#100835). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent GCaMP6f calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

July 8, 2020

Academic Institutions and Nonprofits only

#154867-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-fDIO-hM4D(Gi)-mCherry-WPREpA (#154867). In addition to the viral particles, you will also receive purified pAAV-hSyn-fDIO-hM4D(Gi)-mCherry-WPREpA plasmid DNA. Syn-driven, Flp-dependent hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ulrik Gether

Runegaard et al eNeuro. 2018 Jun 18;5(3). pii: eN-NWR-03

Oct. 8, 2020

Academic Institutions and Nonprofits only

#135632-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-S5E2-GCaMP6f (#135632). In addition to the viral particles, you will also receive purified pAAV-S5E2-GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the E2 regulatory element. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Sept. 13, 2021

Academic Institutions and Nonprofits only

#179460-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-DIO-JEDI-2P-WPRE (#179460). In addition to the viral particles, you will also receive purified pAAV-EF1a-DIO-JEDI-2P-WPRE plasmid DNA. EF1a-driven, Cre-dependent expression of voltage indicator JEDI-2P. These AAV preparations are suitable purity for injection into animals.

Francois St-Pierre

Liu et al Cell. 2022 Aug 16. pii: S0092-8674(22)00

Aug. 22, 2022

Academic Institutions and Nonprofits only

#51084-AAV1

Ready-to-use AAV1 particles produced from AAV-hSyn1-GCaMP6s-P2A-nls-dTomato (#51084). In addition to the viral particles, you will also receive purified AAV-hSyn1-GCaMP6s-P2A-nls-dTomato plasmid DNA. GCaMP6s calcium sensor and bicistronic, physically separate nuclear localized dTomato expression under a human synapsin1 promoter. These AAV preparations are suitable purity for injection into animals.

Jonathan Ting

Aug. 24, 2017

Academic Institutions and Nonprofits only